Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Non-Current Assets (2016 - 2026)

Corvus Pharmaceuticals' Non-Current Assets history spans 12 years, with the latest figure at $798000.0 for Q1 2026.

  • Quarterly Non-Current Assets fell 34.0% to $798000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $798000.0 through Mar 2026, down 34.0% year-over-year, with the annual reading at $904000.0 for FY2025, 31.31% down from the prior year.
  • Non-Current Assets came in at $798000.0 for Q1 2026, down from $904000.0 in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $1.8 million in Q1 2022 to a low of $798000.0 in Q1 2026.
  • The 5-year median for Non-Current Assets is $1.3 million (2023), against an average of $1.3 million.
  • Year-over-year, Non-Current Assets soared 12728.57% in 2022 and then crashed 34.0% in 2026.
  • Corvus Pharmaceuticals' Non-Current Assets stood at $1.7 million in 2022, then decreased by 13.62% to $1.4 million in 2023, then decreased by 7.78% to $1.3 million in 2024, then tumbled by 31.31% to $904000.0 in 2025, then decreased by 11.73% to $798000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Non-Current Assets are $798000.0 (Q1 2026), $904000.0 (Q4 2025), and $1.0 million (Q3 2025).